Wirano

Problems Wirano is committed to solve:

Slow and ineffective enrolment, 

Limited number of patients in a study site database

Difficult for patient to join study on a voluntary basis

Cost of trial 

Solution: 

Connects patients with investigators and investigators with sponsors

Allows patients to find the best study for themselves if they’re willing to participate in a trial

Helps Sponsors / CRO to run feasibility with investigators in real time and to speed up enrolment

The organization of clinical trials is a vulnerable link in the development of new drugs. It is estimated that half of ongoing clinical trials do not meet their patient enrollment targets, and 11% of them do not recruit a single patient.

The feasibility of studies is also a significant challenge for sponsors. A long period, on average 6 months, takes the stage of negotiating and attracting research sites and organizing a new clinical trial.

An international technological IT platform Wirano will allow:
1) within a few days, customers of clinical trials find and conclude a preliminary agreement of intent with researchers who have the technical capabilities and are ready to conduct research in medical institutions;
2) within a few hours, researchers publish information about clinical trials and, in practice, begin recruiting patients who wish to participate in them;
3) within a few minutes, patients find a suitable clinical study, register the necessary information and apply with a specific application for participation in them.

For the first phase of the project, involving patients in clinical trials, our approach has innovative advantages:

1) Visual search tool for suitable clinical trials using a geographic map and intelligent processing of patient profile data (international patent application WIPO93885)
2) Built-in specialized messenger for quick communication with patients with a convenient presentation of information for analysis and decision-making (international patent application WIPO93889)
3) Intelligent agent for automatic translation of queries with "popular" names and professional medical terminology in English online

The innovativeness of the approach for the subsequent phases of the project lies in algorithms for intelligent information processing and an optimized business process for quickly attracting researchers by sponsors to start new clinical trials.

First of all, our solution will be in demand for sponsors (pharmaceutical companies and CROs), as it solves the problem of a quick and reliable start of a clinical research program with control of all stages of the process. Our platform will indirectly reduce the per pationt cost. 

It will also allow orphan patients easily to find research to participate, which in some countries is the only way to get treatment for a rare disease. For patients and researchers, all the features of the service will be free of charge.

The platform will allow to unite all participants of the study, patients to find validated studies for theit deseases around the world.

The main modules of the system:
1) Patient's office with convenient search and selection of a clinical trial with a pre-screening function for admission to the selected clinical trial;
2) Investigator's office with an analytical dashboard and function for starting a clinical trial;
3) Sponsor's office with a business intelligence system, feasibility analysis, planning and organization of a clinical trial program;
4) A specialized messenger for organizing communications of research participants and receiving news through a special news channel;
5) Financial subsystem for the organization of clinical trials by sponsors.

Patient programming interfaces will be translated into local languages where the service will carry out its work.

At the moment, we have a prototype of an IT platform with embedded software, which is available for searching and recruiting patients to a selected pool of clinical trials in Russian and English.

A unique feature of the technological solution of the PatientFacient platform is a specialized information messenger for the rapid organization of communications between participants (a solution in the stage of obtaining patents for a visual interface). An integral part of this messenger is a news channel that can be customized according to the interests of patients and researchers in accordance with the settings of their profiles.

Also, as part of the technological platform, there will be an online constructor for quick setup and organization of the process of connecting patients with pre-screening (collecting the necessary information about the possibility of patient participation). For this solution, the patent landscape for algorithms and visual interface will be investigated.

A distinctive feature of our solution will be the intelligent translation of information from the only language of international clinical trials (English) into the local language of the patient in accordance with the selected setting of his profile. The translation will be bidirectional and its internal engine will use synonyms and intended semantics. For example, typing the word "lupus" would mean two different diseases "systemic lupus erythematosus" - systemic lupus erythematosus and "Lupus vulgaris" - tuberculosis. The query language will also in the online mode clarify the semantics of the disease from the user if it detects the possibility of a different interpretation of the search query. At the moment, there are no similar machine translation systems in the clinical research industry. International patents will be registered on the algorithms of the translation engine.

1. Microsoft Azure
2. Microsoft SQL Server
3. Microsoft Visual Studio
4. C#
5. DevExpress

A specialized Web application has a cloud storage and a centralized logic for processing information about all key events registered in the system: connecting new patients, changing their status, choosing clinical trials by them, entering and changing the status of clinical trials themselves, the activity of researchers and requests from sponsors.

The platform combines four types of role-based interfaces that correspond to ICH terminology: sponsor (pharmaceutical company, customer of clinical trials), researcher (doctor conducting a clinical trial in his medical institution), participant (patient), and service operator. Each role has its own visual interface with functionality. You can select a preferred language for the patient's visual interface. All role-based interfaces have a built-in messenger that is activated only for relevant clinical trials with relevant contacts. From the messenger, there is access to the published profile of the participant, for example, for the researcher to the patient profile with the information necessary for making decisions.

A potential clinical trial participant has a convenient visual search mechanism that makes it easy to find a suitable clinical trial. The built-in messenger is activated either when the profile is completely filled to request participation in the selected study, or automatically from the service, if a suitable study is found for the patient based on the available information. If the patient is already participating in another study, this function is automatically disabled, following the limitations of the clinical trial protocols.

Wirano ia a new technology, which is not widly used so far. 

please find below the link on wirano patent. https://drive.google.com/file/... 

As Wirano will be dealing with sensitive personal patient and investigator data, it will be supported by top-level legal & compliance teams in order to ensure full adherence to the Data Privacy legislation worldwide, including HIPPAA

A the moment the platform is not in active use, at the testing stage. When launching the program next year, we plan to cover more than 1000 people involved within the next 2 years.

Our goal for the next year:

Launch of all main ways of monetization (including subscription)

Develop and test solutions for patients engagement with the platform

5-7 connected sponsors

Up to 20 active clinical trials

250-300 patients found via the platform

10-15 completed feasibility projects

For the next 5 years, geoexpansion is planned to the countries of Europe and Asia. High quality, user-friendliness and a strong marketing campaign will enable us to achieve this.

number of involved sponsors

number active clinical trials

patients found via the platform

completed projects

countries covered

6

Andrey Tarakanov MD, MBA - Chief Executive Officer, co-founder

Vladimir Krechikov MD, Ph., MSc. - Clinical Trials Expert, co-founder

Maria Lapuk - Chief Marketing Officer, co-founder

Noel Quinn - Chief Investment Officer, co-founder

Sergey Kotov - Chief Technology Officer

We have each worked in multi national and etnically diverse environments, with a good understanding of the challenges this brings. This will ensure that we have a diverse and inclusive leadership team and through the whole organisation.

We have a close associate based in London, who has a rare disease and is also a patient scientist advocate involved in EUPATI and various patient groups.

To help speed up the completion of our MVP and the carrying out of our full scale "Pilot Project", which will validate fully our proposal and the commerciality of the project.

To help speed up the completion of our MVP and the carrying out of our full scale "Pilot Project", which will validate fully our proposal and the commerciality of the project.

international pharma, biotech and life sciences companies and other academic institutions, who are involved in areas of relevant interest.